Skip to main content

Alethia Young

Chief Financial Officer, Bicycle Therapeutics

Ms. Young has over 20 years of experience in biopharmaceutical industry. Currently, Ms. Young is the chief financial officer at Bicycle Therapeutics.

Most recently, Ms. Young served as chief financial officer at Graphite Bio, and prior to being at Graphite, Ms. Young was a senior biotech analyst and head of research at Cantor Fitzgerald, managing the equity research department covering large cap and small-mid-cap biotechnology companies. Prior to joining Cantor Fitzgerald in 2018, Ms. Young held senior biotech analyst positions at Credit Suisse and Deutsche Bank. Earlier in her career, she was a research policy analyst and president at Marwood Group, providing healthcare-focused advisory services to institutional investors. She began her career at J.P. Morgan in the investment banking and asset management divisions.

Ms. Young earned a B.A. in Economics and Spanish from Duke University. She currently serves on the board of directors for BUILD NYC.

Careers with Purpose

Explore job opportunities at PTC

Three of PTC's scientists